OTCMKTS:AMBS

Amarantus BioScience Competitors

$0.0099
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.02
Volume228,302 shs
Average Volume775,553 shs
Market Capitalization$3.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1

Competitors

Amarantus BioScience (OTCMKTS:AMBS) Vs. NTEC, NVLNF, NRIFF, MCUJF, CPMD, and CPMD

Should you be buying AMBS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Amarantus BioScience, including Intec Pharma (NTEC), Novelion Therapeutics (NVLNF), Nuvo Pharmaceuticals (NRIFF), Medicure (MCUJF), CannaPharmaRX (CPMD), and CannaPharmaRX (CPMD).

Amarantus BioScience (OTCMKTS:AMBS) and Intec Pharma (NASDAQ:NTEC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Amarantus BioScience and Intec Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarantus BioScienceN/AN/AN/AN/AN/A
Intec PharmaN/AN/A$-47,600,000.00($21.80)-0.17

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Amarantus BioScience and Intec Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarantus BioScience0000N/A
Intec Pharma03102.25

Intec Pharma has a consensus target price of $13.00, indicating a potential upside of 251.35%. Given Intec Pharma's higher possible upside, analysts plainly believe Intec Pharma is more favorable than Amarantus BioScience.

Profitability

This table compares Amarantus BioScience and Intec Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarantus BioScienceN/AN/AN/A
Intec PharmaN/A-93.54%-63.98%

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by insiders. Comparatively, 3.3% of Intec Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amarantus BioScience beats Intec Pharma on 4 of the 6 factors compared between the two stocks.

Novelion Therapeutics (OTCMKTS:NVLNF) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Novelion Therapeutics and Amarantus BioScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novelion Therapeutics0000N/A
Amarantus BioScience0000N/A

Institutional & Insider Ownership

48.6% of Novelion Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Amarantus BioScience shares are held by institutional investors. 3.6% of Novelion Therapeutics shares are held by company insiders. Comparatively, 10.3% of Amarantus BioScience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Novelion Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Profitability

This table compares Novelion Therapeutics and Amarantus BioScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novelion TherapeuticsN/AN/AN/A
Amarantus BioScienceN/AN/AN/A

Earnings and Valuation

This table compares Novelion Therapeutics and Amarantus BioScience's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novelion Therapeutics$130.43 million0.11$-108,330,000.00N/AN/A
Amarantus BioScienceN/AN/AN/AN/AN/A

Amarantus BioScience has lower revenue, but higher earnings than Novelion Therapeutics.

Summary

Novelion Therapeutics beats Amarantus BioScience on 3 of the 4 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and Nuvo Pharmaceuticals (OTCMKTS:NRIFF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Amarantus BioScience and Nuvo Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarantus BioScience0000N/A
Nuvo Pharmaceuticals0000N/A

Volatility and Risk

Amarantus BioScience has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Nuvo Pharmaceuticals has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Amarantus BioScience and Nuvo Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarantus BioScienceN/AN/AN/A
Nuvo Pharmaceuticals-2.81%8.02%1.11%

Valuation & Earnings

This table compares Amarantus BioScience and Nuvo Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarantus BioScienceN/AN/AN/AN/AN/A
Nuvo Pharmaceuticals$52.41 million0.26$2.53 millionN/AN/A

Nuvo Pharmaceuticals has higher revenue and earnings than Amarantus BioScience.

Summary

Nuvo Pharmaceuticals beats Amarantus BioScience on 4 of the 7 factors compared between the two stocks.

Medicure (OTCMKTS:MCUJF) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Medicure and Amarantus BioScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
Amarantus BioScience0000N/A

Institutional and Insider Ownership

0.0% of Amarantus BioScience shares are held by institutional investors. 12.9% of Medicure shares are held by insiders. Comparatively, 10.3% of Amarantus BioScience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Medicure has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.

Profitability

This table compares Medicure and Amarantus BioScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicure-179.92%-63.27%-41.85%
Amarantus BioScienceN/AN/AN/A

Valuation and Earnings

This table compares Medicure and Amarantus BioScience's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicure$15.20 million0.89$-14,910,000.00N/AN/A
Amarantus BioScienceN/AN/AN/AN/AN/A

Amarantus BioScience has lower revenue, but higher earnings than Medicure.

Summary

Amarantus BioScience beats Medicure on 5 of the 7 factors compared between the two stocks.

CannaPharmaRX (OTCMKTS:CPMD) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares CannaPharmaRX and Amarantus BioScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CannaPharmaRXN/A-726.81%-96.06%
Amarantus BioScienceN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for CannaPharmaRX and Amarantus BioScience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CannaPharmaRX0000N/A
Amarantus BioScience0000N/A

Valuation and Earnings

This table compares CannaPharmaRX and Amarantus BioScience's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CannaPharmaRXN/AN/A$-20,450,000.00N/AN/A
Amarantus BioScienceN/AN/AN/AN/AN/A

Institutional and Insider Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 71.9% of CannaPharmaRX shares are owned by insiders. Comparatively, 10.3% of Amarantus BioScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

CannaPharmaRX has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.

Summary

Amarantus BioScience beats CannaPharmaRX on 3 of the 5 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amarantus BioScience and CannaPharmaRX, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarantus BioScience0000N/A
CannaPharmaRX0000N/A

Institutional & Insider Ownership

0.0% of Amarantus BioScience shares are held by institutional investors. 10.3% of Amarantus BioScience shares are held by company insiders. Comparatively, 71.9% of CannaPharmaRX shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Amarantus BioScience and CannaPharmaRX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarantus BioScienceN/AN/AN/A
CannaPharmaRXN/A-726.81%-96.06%

Risk and Volatility

Amarantus BioScience has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, CannaPharmaRX has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Earnings & Valuation

This table compares Amarantus BioScience and CannaPharmaRX's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarantus BioScienceN/AN/AN/AN/AN/A
CannaPharmaRXN/AN/A$-20,450,000.00N/AN/A

Summary

Amarantus BioScience beats CannaPharmaRX on 3 of the 5 factors compared between the two stocks.


Amarantus BioScience Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Intec Pharma logo
NTEC
Intec Pharma
1.4$3.70flat$13.90 millionN/A-0.52
NVLNF
Novelion Therapeutics
0.6$0.70flat$13.77 million$130.43 million0.00Gap Down
NRIFF
Nuvo Pharmaceuticals
0.7$1.20flat$13.68 million$52.41 million30.00
Medicure logo
MCUJF
Medicure
0.6$1.32flat$13.53 million$15.20 million-1.05
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24flat$12.01 millionN/A-0.47Gap Up
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24flat$12.01 millionN/A-0.47Gap Up
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08flat$11.99 millionN/A-3.90
Teligent logo
TLGT
Teligent
1.2$0.52flat$11.64 million$65.90 million-0.06
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04flat$11.46 million$7.38 million0.00Gap Up
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.12flat$10.86 million$4.08 million-1.29Gap Down
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.63flat$10.84 millionN/A-0.84
Williston logo
WHCA
Williston
0.0$0.70flat$9.51 millionN/A0.00
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.12flat$9.25 millionN/A0.00News Coverage
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.40flat$8.93 million$2.66 million-13.47
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.51flat$8.51 millionN/A0.00Gap Up
ULUR
ULURU
0.3$0.28flat$8.17 millionN/A0.00
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.13flat$7.32 millionN/A0.00News Coverage
Gap Down
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36flat$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.07flat$6.39 millionN/A0.00Gap Up
KAYS
Kaya
0.7$0.44flat$6.38 million$1.01 million0.00
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.05flat$5.71 million$30,000.000.00Gap Up
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$5.32 millionN/A0.00High Trading Volume
Gap Up
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.21flat$4.81 million$3.48 million-1.76Gap Down
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.57flat$4.07 million$9.47 million0.00High Trading Volume
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09flat$3.75 million$3.65 million0.00News Coverage
Gap Down
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.36 millionN/A0.00Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14flat$2.88 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$2.85 million$2 million0.00
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.82 millionN/A-0.09News Coverage
Gap Up
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.45flat$1.87 millionN/A0.00Gap Up
NSPX
Inspyr Therapeutics
0.5$0.01flat$1.83 millionN/A0.00Gap Up
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04flat$1.78 million$530,000.000.00Gap Up
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$1.70 million$20,000.00-0.77
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.45flat$1.57 millionN/A0.00News Coverage
Gap Up
Cardax logo
CDXI
Cardax
0.0$1.95flat$1.55 million$710,000.000.00High Trading Volume
Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
HSTC
HST Global
0.8$0.26flat$1.36 millionN/A0.00Gap Down
WWHC
W World
0.8$4.90flat$1.33 millionN/A0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.29 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22flat$1.17 millionN/A0.00Decrease in Short Interest
Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Upcoming Earnings
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$991,000.00N/A0.00
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$991,000.00N/A0.00
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$928,000.00N/A0.00Gap Down
ATRX
Adhera Therapeutics
0.0$0.07flat$872,000.00$250,000.000.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.06flat$865,000.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.